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Abstract
Background: Neuroticism is a major risk factor for affective disorders. This personality trait has been hypothesized to 
associate with synaptic availability of the serotonin transporter, which critically controls serotonergic tone in the brain. 
However, earlier studies linking neuroticism and serotonin transporter have failed to produce converging findings. 
Because sex affects both the serotonergic system and the risk that neuroticism poses to the individual, sex may modify 
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the association between neuroticism and serotonin transporter, but this question has not been investigated by previous 
studies.
Methods: Here, we combined data from 4 different positron emission tomography imaging centers to address whether 
neuroticism is related to serotonin transporter binding in vivo. The data set included serotonin transporter binding potential 
values from the thalamus and striatum and personality scores from 91 healthy males and 56 healthy females. We specifically 
tested if the association between neuroticism and serotonin transporter is different in females and males.
Results: We found that neuroticism and thalamic serotonin transporter binding potentials were associated in both males 
and females, but with opposite directionality. Higher neuroticism associated with higher serotonin transporter binding 
potential in males (standardized beta 0.292, P = .008), whereas in females, higher neuroticism associated with lower serotonin 
transporter binding potential (standardized beta -0.288, P = .014).
Conclusions: The finding is in agreement with recent studies showing that the serotonergic system is involved in affective 
disorders differently in males and females and suggests that contribution of thalamic serotonin transporter to the risk of 
affective disorders depends on sex.
Keywords: neuroticism, sex, serotonin, serotonin transporter, PET
Introduction
Women have higher incidence of major depressive disor-
der (MDD) and subclinical depressive symptoms than men 
(Lindeman et al., 2000). The neurotransmitter mechanisms that 
might contribute to this difference are still not well under-
stood. On average women score higher in neuroticism, which is 
a personality trait that reflects the propensity for experiencing 
negatively valenced emotional states. By definition, individu-
als on the higher end of the neuroticism spectrum are more 
prone to feel negative emotions such as sadness and anxious-
ness and also have more difficulties when trying to cope with 
stress (Costa and McCrae, 1992a). Higher neuroticism scores 
also increase the risk for developing MDD (Kendler et al., 2006) 
and anxiety disorders (Hettema et al., 2006). Thus, sex differ-
ences in manifesting this trait may contribute to the sex dif-
ference in the incidence of MDD. Moreover, high neuroticism 
also increases the risk for MDD more so in women than in men 
(Kendler and Gardner, 2014), which suggests that sex impacts 
the mechanism through which neuroticism confers greater risk 
for affective disorders.
The sex difference in the incidence of MDD putatively is 
mediated at least partly by the effects of sex hormones, because 
the MDD incidence is higher in women only after puberty (Wade 
et al., 2002). Further, sex hormones affect the serotonin system 
in multiple ways (Barth et al., 2015), which may be one mecha-
nism conveying the effects of sex on the incidence of affective 
disorder. Serotonergic function has a well-documented role in 
the pathophysiology of MDD and the mechanisms of antide-
pressant pharmacotherapy (Cannon et  al., 2007; Meyer, 2007; 
Sharp and Cowen, 2011). The synaptic serotonin levels are cru-
cially controlled by the serotonin transporter (5-HTT). Thus, 
the 5-HTT has been viewed as a promising target in the search 
for the neural underpinnings of neuroticism. Investigating the 
central 5-HTT in neuroticism may elucidate the neurobiologi-
cal mechanisms of the greater susceptibility for developing 
MDD and thereby illuminate the etiology of affective disorders 
(Marcus et al., 2008).
Despite initially promising findings, human studies linking 
5-HTT and neuroticism have been inconsistent, and the role 
of 5-HTT in neuroticism has remained elusive. The S-allele in 
the 5-HTT gene-linked promoter region (5-HTTLPR) was ini-
tially found to be associated with higher neuroticism (Lesch 
et  al., 1996). However, subsequently several negative findings 
have been published, and the latest meta-analyses have yielded 
inconclusive results, mainly due to the large heterogeneity in 
the results across studies (Munafo et  al., 2009; Minelli et  al., 
2011). Intriguingly, recent evidence converges to suggest that 
sex may modulate the effects of 5-HTTLPR polymorphism on 
phenotype (Gressier et al., 2016). That is, in females, the S-allele 
seems to associate more with depression and negative affect, 
whereas in males it associates more with aggressive and exter-
nalizing traits.
So far, 3 published positron emission tomography (PET) stud-
ies have investigated whether neuroticism associates with in 
vivo 5-HTT binding. Takano and colleagues (Takano et al., 2007) 
found a positive association between neuroticism and thalamic 
5-HTT binding, Klaver et al. (Klaver et al., 2007) a negative rela-
tionship, while Kalbitzer and colleagues (Kalbitzer et  al., 2009) 
did not detect any significant relationship between these 2 
measures. On explanation may be that single site PET studies 
often lack power due to too-small sample sizes. Moreover, the 
first study included only males, whereas the latter ones included 
both males and females. To date, no study has directly investi-
gated whether sex modulates the effect of neuroticism on 5-HTT 
binding. If such a sex effect exists, it might also explain incon-
sistencies in the literature and elucidate the neurobiological 
basis for the greater incidence of MDD in women and the ten-
dency for women to manifest a partly distinct symptom profile 
than men during major depressive episodes (Martin et al., 2013).
Significance Statement
Neurobiological underpinnings of the personality trait neuroticism are still not well understood. Here, using a large sample, 
we show that higher neuroticism associates with higher thalamic serotonin transporter binding in males, whereas in females, 
higher neuroticism associates with lower thalamic serotonin transporter binding. The finding helps to elucidate the brain-level 
molecular mechanisms predisposing to affective disorders. The study also provides clues into the neural mechanisms of sex 
differences in many psychiatric illnesses.
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In the present study, we sought to resolve these conflicts in 
previous PET imaging studies regarding the association between 
5-HTT and neuroticism. We combined data from 4 different 
imaging centers that have measured the 5-factor model person-
ality questionnaire and 5-HTT binding using PET with a selective 
5-HTT radiotracer. Importantly, the combined data set was large 
enough to allow us to test whether sex modulates the associa-
tion between neuroticism on 5-HTT binding. Because previous 
studies have found correlations between other personality traits 
and 5-HTT (Kalbitzer et al., 2009), we also explored these asso-
ciations in this data set.
Methods
Study Design
The study sample comprises 147 healthy subjects (91 males 
and 56 females) from 4 independent imaging centers (Table 1). 
The imaging centers were: the National Institute of Radiological 
Sciences, Chiba, Japan (NIRS), the Neurobiology Research Unit, 
Copenhagen University Hospital Rigshospitalet, Denmark (NRU), 
the National Institute of Mental Health, Bethesda, Maryland, USA 
(NIMH), and the Turku PET Centre, Turku, Finland (TPC). NIRS, 
NRU, and NIMH have previously published these data (Klaver 
et al., 2007; Takano et al., 2007; Kalbitzer et al., 2009; Erritzoe et 
al., 2010). In addition, unpublished data from 31 subjects were 
collected at the TPC, following the same methods described in 
Tuominen et al. (Tuominen et al., 2012). The protocols of the 
original studies were approved by local ethics committees, and 
subjects gave informed consent accepted by those committees. 
The study at the NIRS was approved by the Ethics and Radiation 
Safety Committee of the National Institute of Radiological 
Sciences, Chiba, Japan; the study at the NRU was approved by the 
Ethics Committee of Copenhagen and Frederiksberg, Denmark; 
the study at the NIMH was approved by the Institutional Review 
Board at the National Institute of Mental Health, Bethesda, MD; 
and the study at the TPC was approved by the by the Joint Ethical 
Committee of the University of Turku and the Turku University 
Central Hospital, Turku, Finland. At the NIHM and Turku PET 
Centre, subjects were interviewed using the Structured Clinical 
Interview for DSM-IV, whereas at the NIRS and NRU the subjects 
underwent an unstructured interview. At all study sites, exclu-
sion criteria included lifetime psychiatric illness and present 
substance abuse. At the TPC, serotonin transporter binding was 
measured using [11C]MADAM (Lundberg et al., 2005) and person-
ality traits using NEO-FFI (Costa and McCrae, 1992b), whereas 
other centers used [11C]DASB (Houle et al., 2000) and NEO-PI-R 
scale (Costa and McCrae, 1992a). To account for the different 
number of items in the NEO-PI-R and NEO-FFI, we calculated 
a mean neuroticism score for each individual by dividing the 
raw score by the number of items in the neuroticism scale. 
Thus, neuroticism scores ranged from 0 to 4 (each item is rated 
from 0 to 4). The PET data were collected with Siemens ECAT47 
at the NIRS, with HRRT scanner (Siemens) at the TPC, and with 
GE-Advance scanner (General Electric) at the NRU and NIHM. 
The data were modeled at the TPC using the simplified refer-
ence tissue model (Lammertsma and Hume, 1996) and at other 
centers using the multi-linear reference tissue model 2 (Ichise 
et al., 2003) with cerebellar gray matter as the reference region. 
These models allow the estimation of the nondisplaceable bind-
ing potential (BPND; Innis et al., 2007), which equals fND Bavail/KD, 
where fND is the free fraction of ligand in the nondisplaceable 
tissue compartment, Bavail is concentration of available receptors, 
and KD is radioligand equilibrium dissociation constant. BPND is 
directly proportional to the density of 5-HTTs and therefore 
can be used as an index of their density. All the imaging data 
included into the present study were preprocessed and mod-
eled at the respective center with the primary study in mind. 
The current analyses were performed using only the regional 
BPND values that were available. Voxel-wise BPND maps were not 
available.
At the NRU, regions-of-interest (ROIs) were delineated auto-
matically (Svarer et al., 2005), whereas in other centers ROIs 
were delineated manually onto individual PET scans using the 
co-registered T1-weighted MRI scan. All 4 centers had deline-
ated thalamus as an ROI, but otherwise the centers used dif-
ferent ROIs (supplementary Table 1). At the NIRS, the striatum 
was delineated as one ROI, whereas in the other 3 centers this 
ROI was divided into caudate and putamen. Because serotonin 
transporter binding in the caudate and putamen is highly cor-
related (Tuominen et al., 2014) and we did not have the sizes 
of each individual’s ROIs, we computed an arithmetic mean of 
BPNDs in the caudate and putamen and used that as an estimate 
of striatal BPND for the data from 3 centers that had delineated 
these regions separately. No other region in the brain was con-
sistently defined by all the centers, and therefore the statisti-
cal analyses were confined to these 2 regions: the thalamus and 
striatum.
Statistical Methods
To better assess the effects of sex and age on the association 
between neuroticism and 5-HTT BPNDs, individual data points 
were included into the statistical model instead of carrying out 
Table 1. Details of the Data Collected at Each Center
Center N (M/F) Age Neuroticisma Questionnaire Tracer
Serotonin transporter BPND
Thalamus Striatum 
NIRS1 31 (31/0) 23.6 ± 2.8 2.1 ± 0.46 NEO-PI-R [11C]DASB 1.8 ± 0.29 1.3 ± 0.16
NRU2 57 (37/20) 35.1 ± 18.0 1.5 ± 0.40 NEO-PI-R [11C]DASB 1.8 ± 0.25  1.6 ± 0.18b
NIMH3 28 (8/20) 36.3 ± 9.1 1.9 ± 0.14 NEO-PI-R [11C]DASB 1.7 ± 0.23  1.3 ± 0.17b
TPC4 31 (15/16) 39.1 ± 5.1 1.2 ± 0.76 NEO-FFI [11C]MADAM 1.4 ± 0.15  1.1 ± 0.16b
Values are presented as mean ± SD. 
aNeuroticism score ranges from 0 to 4 (each item is rated from 0 to 4) and was calculated by dividing the raw score by the number of items in 
the questionnaire. 
bArithmetic mean of nondisplaceable binding potential (BPNDs) in the caudatus and putamen. 1, National Institute of Radiological Sciences, 
Chiba, Japan; 2, Neurobiology Research Unit, Copenhagen University Hospital Rigshospitalet, Denmark; 3, National Institute of Mental Health, 
Bethesda, MD; 4, Turku PET Centre, Turku, Finland.
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a meta-analysis. Multiple linear regression analyses using the 
individual data were performed for the 2 brain regions (thala-
mus and striatum) separately. The 5-HTT BPND was used as the 
dependent variable, and the neuroticism*sex interaction term, 
neuroticism, sex, and age as independent variables. The differ-
ent centers were coded as dummy variables and included as 
covariate in all statistical models. The interaction term was cre-
ated by multiplying sex and neuroticism values. We predicted 
that the interaction term would significantly associate with 
5-HTT BPND. To explore if data from a single center dominated 
the effect, we also carried out this analysis 4 other times, leaving 
one center at the time out from the analysis. To obtain estimates 
of standardized beta coefficients for males and females sepa-
rately, multiple regression analyses were performed separately 
for both sexes with the 5-HTT BPND as the dependent variable, 
and neuroticism, age, and centers as independent variables.
To illustrate the results in the thalamus, a partial regression 
plot (Larsen and McCleary 1972) between neuroticism scores and 
the thalamic 5-HTT BPND values was created. First, we computed 
residuals for both sexes by regressing the 5-HTT BPND against 
the age and centers while omitting neuroticism scores from 
the model. Second, we computed residuals for both sexes by 
regressing neuroticism against the age and centers while omit-
ting 5-HTT BPND values from the model. The resulting residual 
vectors can be understood as mean centered neuroticism scores 
corrected for the age and centers, and mean centered 5-HTT 
BPND values corrected for the age and center respectively. Finally, 
the residual vectors for both sexes from the above 2 regression 
analyses were plotted against each other.
Because previous studies have reported associations 
between other personality traits and serotonin transporter BPND 
(Kalbitzer et  al., 2009), we also performed exploratory multi-
ple linear regression analyses for the other 4 personality traits 
included in the inventory: extraversion, agreeableness, openness 
to experience, and conscientiousness. Despite some reports of 
associations between these personality traits and the serotonin 
system, there are no compelling theoretical reasons to assume 
that these personality traits are associated with the serotonin 
system. Thus, these analyses were considered as exploratory. In 
a similar manner, the model included 5-HTT BPND as the depend-
ent variable, and personality trait, sex, age, and the centers as 
independent variables. As we did not have a priori hypothesis 
about sex interaction for other personality traits, the interaction 
term was not included into the analyses.
Results
Neuroticism and 5-HTT in the Thalamus
A statistically significant multiple linear regression was found 
using the thalamic BPND values as the dependent variable 
and neuroticism, neuroticism * sex, sex, age, and centers as 
independent variables (F(7,139)  =  14.566, P < .001, R
2  =  .394). The 
5-HTT BPND in the thalamus was significantly associated with 
the neuroticism*sex interaction term (t  =  2.749, standardized 
β = 0.963, P = .007) and with the age term (t = -2.542, standard-
ized β = -.288, P = .014). The multiple linear regression analyses 
for each sex separately using the thalamic BPND values as the 
dependent variable and neuroticism, age, and centers as inde-
pendent variables were also significant (males: F(5,85) = 11.385, P < 
.001, R2 = .366; females: F(4,51) = 13.011, P < .001, R
2
 = .466). In males, 
neuroticism was a significant positive predictor of thalamic 
5-HTT BPND (t = 2.707, standardized β = .292, P = .008), whereas in 
females, neuroticism was a significant negative predictor and a 
negative association (t = -2.542, standardized β = -.288, P = .014). 
As illustrated in the partial regression plot (Figure  1), higher 
neuroticism scores in males were associated with higher 5-HTT 
BPND values in the thalamus, whereas higher neuroticism scores 
in females were associated with lower BPND values in the same 
region. Results from excluding one center at a time from the 
analyses are shown in supplementary Material and supplemen-
tary Figure 1.
Neuroticism and 5-HTT in the Striatum
The multiple linear regression model using the striatum BPND 
as the dependent variable and neuroticism, neuroticism * sex, 
sex, age, and centers as independent variables was statistically 
significant (F(7,139) = 20.022, P < .001, R
2 = .477). However, no signifi-
cant main effect of neuroticism or sex by neuroticism interac-
tion was observed on the striatal 5-HTT BPND.
Extraversion, Agreeableness, Openness to 
Experience, and Conscientiousness and 5-HTT
Multiple regression analyses, using the other 4 personality traits 
(extraversion, agreeableness, openness to experience, and con-
scientiousness) were also carried out. However, in the resulting 
regressions models, none of these other personality traits were 
statistically significant predictors of the 5-HTT BPND in the thala-
mus or striatum (all P > .05).
Conclusions
The present study is the largest PET study to date that has 
examined the in vivo molecular brain biology basis of personal-
ity. The multi-site approach allowed us for the first time to show 
Figure 1. Partial regression plot illustrates the associations between neuroticism 
score and the thalamic serotonin transporter binding potential (5-HTT BPND) in 
males and females. Adjusted neuroticism scores are the residuals when regress-
ing the neuroticism scores against age and center while omitting 5-HTT BPND 
values. Adjusted thalamic 5-HTT BPND values are the residuals when regressing 
BPND values against age and center while omitting neuroticism scores. Thus, the 
adjusted scores can be viewed as mean centered neuroticism scores and BPND 
values that have been corrected for age and study center.
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that neuroticism and 5-HTT are linked in a sex-dependent man-
ner. More specifically, in males, higher neuroticism scores asso-
ciated with higher thalamic 5-HTT binding, whereas in females, 
high neuroticism scores associated with lower 5-HTT binding in 
the thalamus. In contrast, other personality traits described by 
the 5-factor model were not significantly associated with 5-HTT 
binding.
The interpretation between the magnitude of 5-HTT bind-
ing and intrasynaptic 5-HT levels is complex. Under some 
experimental conditions, higher 5-HTT binding correlates with 
decreased serotonin metabolite concentrations in the cere-
brospinal fluid (Heinz et al., 1998, 2002). Nevertheless, the cell 
surface expression of 5-HTT sites generally parallels seroto-
nin levels, as the cell surface expression of 5-HTT sites rapidly 
responds to changing serotonin concentrations (Blakely et  al., 
1998). Furthermore, the extent to which 5-HTT binding simply 
reflects the number of serotonergic afferents to projection areas 
is unknown. Thus, our data may not support simplistic hypothe-
ses regarding the relationship between neuroticism ratings and 
synaptic serotonin levels per se.
An increasing body of literature supports the involvement 
of the cerebral serotonin system in neuroticism. Frokjaer and 
colleagues (Frokjaer et  al., 2008) showed that higher neuroti-
cism scores associate with higher 5-HT2A receptor binding in 
the frontolimbic regions (n = 83). More recently, we found that 
both cortical and subcortical 5-HT1A receptor binding is lower in 
subjects who have higher neuroticism scores (Hirvonen et al., 
2015) (n = 34). Decreased 5-HT1A and increased 5-HT2A recep-
tor binding in subjects with high neuroticism could result as 
compensatory changes to low serotonin levels (Hirvonen et al., 
2015), which in turn have been linked to negative emotional-
ity and depressive mood. For instance, low serotonin levels are 
associated with a negative emotional processing bias including 
an increase in the responsiveness to punishment (Cools et al., 
2008; Fisher et al., 2015) and, in susceptible subjects, depressive 
symptoms (Benkelfat et  al., 1994). In summary, the literature 
suggests that lower synaptic serotonin levels underlie higher 
neuroticism scores. Given the present results, we speculate 
that sex also affects the association between neuroticism and 
other constituents of the serotonin system. In this sample, 
we did not find a difference in 5-HTT BPND in the thalamus or 
striatum between males and females, but there is some evi-
dence that healthy women have higher 5-HT1A binding (Parsey 
et al., 2002) and lower serotonin synthesis rate (Nishizawa et al., 
1997; Sakai et al., 2006) than males. Whether neuroticism cor-
relates with serotonin synthesis rate or 5-HT1A binding in a sex-
dependent manner is currently unknown. Such an interaction 
could potentially have opposing effects with the present find-
ing on the intrasynaptic serotonin levels and could help explain 
why 5-HTT binding associates with neuroticism differently in 
men and women. Despite that the exact molecular interpreta-
tion of our finding remains elusive, it clearly demonstrates that 
the underlying neurobiology of neuroticism is at least, to some 
extent, different between the sexes.
We found that neuroticism was associated with 5-HTT bind-
ing in a sex-dependent manner in the thalamus but not in the 
striatum. The mediodorsal and periventricular nuclei of the 
thalamus form part of the extended medial prefrontal network, 
which is centrally involved in MDD (Price and Drevets, 2010). 
Within that network, these thalamic nuclei putatively process, 
gate, and relay information from subcortical structures to the 
prefrontal cortex. Disrupting thalamic function by lesion leads to 
higher acute and chronic stress responses (Bhatnagar et al., 2002; 
Spencer et al., 2004), demonstrating its role in stress regulation. 
In MDD patients, thalamic metabolism is increased (Price and 
Drevets, 2010; Su et al., 2014), but whether the thalamic 5-HTT 
binding is different in MDD patients has remained elusive. 
Previous PET studies have found both increased and decreased 
5-HTT binding in the thalamus in MDD patients (Savitz and 
Drevets, 2013). Similarly, the literature is mixed on whether MDD 
associates with increases or decreases in 5-HT1a and 5-HT2a 
receptors (Shrestha et al., 2012; Savitz and Drevets, 2013).
Unfortunately, psychiatric imaging studies have rarely taken 
into account the possible modifying effects of sex. The few studies 
that have done so suggest that there may be important sex differ-
ences in the neurobiology of affective disorders. Recent data has 
shown that patients with seasonal affective disorder have upregu-
lated cerebral 5-HTT in the winter, whereas individuals that are 
resilient to the disorder have downregulated 5-HTT (Mc Mahon 
et al., 2016). This result was mostly driven by the female partici-
pants. The sex-specific differences may also apply to other parts of 
the serotonin system. Serotonin synthesis capacity may be higher 
in female MDD patients than in male patients (Frey et al., 2010). 
On the other hand, one study reported that male MDD patients 
have elevated 5-HT1A receptor levels but females do not (Kaufman 
et al., 2015). A similar sex difference has been shown in patients 
with panic disorder: male patients have higher 5-HTT levels than 
male controls, whereas 5-HTT binding did not significantly differ 
between female patients and female controls (Maron et al., 2011; 
Cannon et al., 2013). Our results support putative sex differences 
in the neurobiology of affective disorders. Because neuroticism 
is a major risk factor for affective disorders, our results further 
suggest that sex differences are critical in the brain architecture 
of risk for MDD. Indeed, even the 5-HTTLPR polymorphism may 
affect males and females differently. Gressier and colleagues 
(Gressier et  al., 2016) showed that females suffering from MDD 
more often had the S-allele, whereas males with MDD more often 
had the L-allele. The S-allele leads to a lower number of 5-HTT 
proteins, which is detected as lower binding in PET studies (Willeit 
and Praschak-Rieder, 2010). Neuroticism can be viewed as an 
intermediary endophenotype between genetic predisposition and 
an affective disorder. The present study further demonstrates this 
endophenotype has different neurobiological correlates of risk for 
affective disorders in males and females.
Limitations
Results from this study should be appraised in the context of a 
number of limitations. First, women experience more subclini-
cal depressive symptoms compared with men (Lindeman et al., 
2000). Especially in a cross-sectional setting, it is difficult to dis-
entangle high neuroticism personality from subclinical depres-
sion. Thus, it is possible that the negative association in females 
is partially mediated by subclinical depressive symptoms rather 
than associated with neuroticism personality trait per se. 
Second, we did not measure the phase of the menstrual cycle 
in females nor did we have sex steroid hormone levels avail-
able for the females. Although sex steroid hormones affect the 
5-HT2A receptor density (Moses et al., 2000; Kugaya et al., 2003; 
Moses-Kolko et al., 2003) and high-dose sex steroid hormones 
also affect the 5-HTT binding (Kranz et al., 2015), differences in 
the phase of the menstrual cycle are unlikely to contribute to 
the finding in females as the phase does not affect 5-HTT bind-
ing (Jovanovic et al., 2009; Frokjaer et al., 2015).
Another limitation is that individual body mass index (BMI) 
values were not available, and therefore we did not adjust the 
regressions for BMI. Erritzoe and colleagues showed an inverse 
association between BMI and 5-HTT binding (Erritzoe et  al., 
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2010). Because higher neuroticism typically associates with 
higher BMI (Vainik et al., 2013), spurious variations in BMI could 
not explain the positive association seen in males, but such vari-
ations could potentially contribute to the negative association 
seen in females. Finally, the amount of daylight has an effect 
on 5-HTT BPND (Praschak-Rieder et al., 2008), and this effect may 
depend on 5-HTTLPR status (Kalbitzer et al., 2010), which in itself 
has a moderate effect on 5-HTT BPND (Savitz and Drevets, 2013). 
In the present study, neither 5-HTTLPR status nor seasonal vari-
ations were controlled for.
Combining data from 4 independent centers also inherently 
introduces methodological discrepancies. In this study, a num-
ber of potentially confounding methodological differences were 
present between centers. First, neuroticism was measured using 
NEO-PI-R in all centers except one, where a shorter version of the 
NEO-PI, called NEO-FFI, was used. Because correlation between 
NEO-PI-R and NEO-FFI neuroticism scores ranges between 0.89 
and 0.92 (Costa and McCrae, 1992b), differences between these 
instruments are unlikely to affect the results. Second, different 
centers used different PET scanners, which may have affected 
the 5-HTT BPND estimates. Further, the ROI’s were delineated dif-
ferently across the centers. The thalamus and striatum are eas-
ily distinguishable from the PET and T1-weighted MRI and are 
therefore easy to delineate. However, as the 5-HTT BPND is not 
uniform even within these structures, differences in the deline-
ation procedures may have introduced some error variance into 
the BPND estimates. Moreover, 5-HTT binding was measured with 
2 different tracers, [11C]MADAM and [11C]DASB. Both tracers bind 
specifically to the 5-HTT (Emond et al., 2002; Wilson et al., 2002), 
and the rank values and test-retest variability of different regions 
are highly comparable (Kim et al., 2006; Lundberg et al., 2006). 
There are no published head-to-head comparisons between the 
2 tracers, but [11C]MADAM seems to give somewhat lower BPND 
values, at least in the regions included. However, systematically 
lower 5-HTT binding values in a single sample are unlikely to 
affect the overall finding, because centers effects were statis-
tically adjusted for. Additionally, we tested whether our find-
ing would remain the same if the centers would be excluded, 
one at a time, from the analysis. These analyses showed that 
excluding the study that used [11C]MADAM made the neuroti-
cism by sex interaction an even more significant predictor of the 
5-HTT BPND in the model. Surprisingly, after excluding the NRU 
sample, the interaction effect was no more statistically signifi-
cant. This may be simply due to the fact that the NRU sample is 
the largest sample, and excluding it reduced the power of our 
analysis. Nonetheless, these analyses highlight the importance 
of large data sets to discover associations between behavior 
and brain neurotransmitter systems. Finally, in our study we 
did not look for associations beyond thalamus and striatum, as 
no other regions were consistently delineated by all the cent-
ers. Moreover, the delineation methods were likely to be more 
variable across the centers for other regions compared with the 
thalamus and striatum, which are easily distinguishable from 
the PET and T1-weighted MRI. Therefore, this combined data set 
cannot assess if the difference in the neuroticism by sex interac-
tion in the 5-HTT BPND extends beyond the thalamus and stria-
tum. Future studies must elucidate if the results extend to other 
brain regions.
In summary, we found that in males, neuroticism associ-
ates positively with 5-HTT binding in the thalamus, whereas 
in females the association was negative. Our results bridge the 
gap between genetic studies and clinical PET imaging studies 
that both have shown evidence for sex differences in how the 
serotonin system is involved in the pathophysiology of affective 
disorders. This finding underscores the importance of taking 
sex into account when studying normal brain function. Better 
understanding of sex effects will hopefully facilitate better 
understanding of the etiology of psychiatric disorders. Since 
many published single-site PET studies lack power due to too-
small sample sizes, the approach to combine many data sets 
applied here should be encouraged in the molecular imaging 
field. In summary, our results suggest that thalamic 5-HTT could 
contribute differently to the risk of affective disorders in males 
and females. Future studies need to elucidate if similar sex dif-
ferences exist in other constituents of the serotonin system.
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